InflaRx (IFRX) director Brudnick reports shares and multiple stock option grants
Rhea-AI Filing Summary
InflaRx N.V. director Richard Brudnick has filed an initial ownership report showing existing equity holdings. He directly holds 50,000 Ordinary Shares and multiple stock options over additional Ordinary Shares with exercise prices between $1.17 and $2.41 per share, expiring from 2029 through 2036. Most option grants are already fully vested and exercisable, while a January 2026 grant for 30,000 shares will vest in four equal quarterly installments of 7,500 shares, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Brudnick Richard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,450 shares (Direct);
Ordinary Shares — 50,000 shares (Direct)
Footnotes (1)
- This option was granted on February 4, 2019 and is fully vested and exercisable as of the date hereof. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
